STRATEGIC NEWS WATCH — July 2, 2026
|
Roche’s divarasib outright beating both approved KRAS G12C inhibitors head-to-head in Phase 3 rewrites the competitive order of a market Amgen built — a first-mover lead rarely survives a clean superiority readout on both progression-free and overall survival. Today’s top developments:
|
What to Watch
- Roche’s divarasib filing — With head-to-head superiority over both approved KRAS G12C inhibitors now in hand, watch for Roche to move quickly to an NDA submission, and for Amgen and BMS to counter with combination regimens or next-generation candidates to defend a franchise whose first-mover advantage just eroded.
- Itvisma EU market access — As the first gene replacement therapy cleared in the EU for older children, teens and adults with SMA, the decisive test shifts to national reimbursement negotiations and how a one-time fixed dose is priced against ongoing-treatment options already entrenched across European markets.
- AstraZeneca’s China strategy — Following the $1.77B CSPC renal pact, watch for early candidate nominations and whether intensifying geopolitical scrutiny of Sino-Western biopharma partnerships reshapes the structure or pace of AZ’s China-sourced dealmaking.
- Casgevy pediatric rollout — The age-2 expansion widens the addressable population, but the binding constraint is operational: qualified treatment center capacity and payer coverage for a costly one-time therapy will determine how fast newly eligible children actually reach treatment.
- AI-discovery deal validation — The Insilico–Takeda tie-up adds to a run of large-pharma partnerships that increasingly serve as external proof points for AI-native platforms; milestone progress and any pipeline nominations will signal whether these deals convert into durable licensing value.
This brief highlights the edition’s top stories. Read the full July 2, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.